Equine arteritis virus (EAV) is an enveloped virus with a single-stranded, positive-sense RNA genome of approximately 12.7 kb and belongs to the family *Arteriviridae* in the order *Nidovirales* ([@bib6], [@bib22]). The genomic RNA comprises nine known open reading frames (ORFs) flanked by 5′- and 3′-untranslated regions (UTRs) ([@bib22], [@bib24]). The two most 5′-proximal ORFs (1a and 1b) encode two replicase polyproteins (pp1a and pp1ab) and the remaining seven ORFs (2a, 2b, and 3-7) located in the 3′-proximal one-quarter of the genome encode the envelope proteins E, GP2, GP3, GP4, GP5, M, and the nucleocapsid protein (N), respectively ([@bib23]).

EAV is the causative agent of equine viral arteritis (EVA) and is widely distributed in equine populations throughout the world ([@bib30]). A variable percentage (10--70%) of stallions acutely infected with EAV can become persistently infected carriers, shedding the virus constantly in semen ([@bib30]). Persistently infected stallions are the principal reservoir of EAV and are responsible for perpetuation and dissemination of EAV in equine populations ([@bib29], [@bib30], [@bib31]). Further, the long-term carrier state in the stallion allows the generation of genetic and phenotypic diversity of EAV ([@bib2], [@bib3], [@bib10]). There is evidence that establishment and maintenance of the carrier state in stallions is testosterone-dependent. However, many aspects of the biology and immunology underlying viral persistence remain to be elucidated ([@bib11], [@bib12], [@bib16]). Despite the significant biological and economic consequences of persistent EAV infection, there is to date no fully validated therapeutic strategy, except surgical castration, to eliminate the carrier state ([@bib30]).

Phosphorodiamidate morpholino oligomers (PMO) comprise a class of single-stranded oligonucleotide analogues that contain the same purine and pyrimidine bases as DNA but possess a backbone composed of morpholine rings and phosphorodiamidate intersubunit linkages instead of the deoxyribose and phosphodiester components of DNA ([@bib28]). PMO can act as antisense agents by Watson--Crick base pairing with complementary RNA target sequence, thus forming a steric blockade and interfering with gene expression ([@bib25], [@bib27]). PMO are water-soluble, nuclease-resistant and are typically synthesized to be 20--25 subunits in length ([@bib27]). The covalent conjugation of an arginine-rich cell-penetrating peptide (CPP) to the PMO 5′-terminus has been found to greatly improve delivery of PMO into cells ([@bib1], [@bib7], [@bib17]). Peptide-conjugated PMO (PPMO) have been shown to inhibit amplification of a number of RNA viruses in cell culture and mouse models (reviewed by [@bib26]), including the arterivirus, porcine reproductive and respiratory syndrome virus ([@bib9], [@bib20], [@bib21], [@bib36]) and the coronaviruses, mouse hepatitis virus and SARS-CoV ([@bib5], [@bib18], [@bib19]). Previous studies with PRRSV ([@bib20]) and EAV ([@bib32]) have shown that PPMO targeting the 5′-terminal region of the respective arteriviral genomes were particularly effective at inhibiting virus infection. [@bib32] concluded that the mechanism of action by which EAV 5′-UTR-directed PPMO suppressed virus production was likely by inhibiting the translation of the pp1a and pp1ab.

We recently established an *in vitro* model of EAV persistence in HeLa cells for the purpose of furthering our understanding of EAV biology in general and viral persistence in the stallion in particular ([@bib34], [@bib35]). The objective of the current study was to investigate whether an EAV-specific PPMO could effectively eliminate virus from persistently infected HeLa cells.

Our study employed an antisense PPMO targeting the 5′-terminal region of the EAV genome (EAV5′24: 5′-TATGGCACCATACACACTTCGAGC-3′, nucleotide positions 1--24 of the VB strain of EAV, GenBank accession number [DQ846750](ncbi-n:DQ846750)) and a random sequence negative control 22mer PPMO (SCR: 5′-TGCTCTGTCTACAGTAGTGTCA-3′). The CPP (RXR)~4~XB (where R = arginine, X = 6-aminohexanoic acid and B = beta-alanine) was covalently conjugated to the 5′-end of each PMO. The synthesis, purification and analysis of EAV5′24 PPMO and SCR PPMO were performed at AVI BioPharma Inc. (Corvallis, OR) using methods previously described ([@bib1], [@bib28]). The potential cytotoxicity of each PPMO was evaluated in normal HeLa-H cells and in HeLa-H cells persistently infected with EAV. Briefly, normal HeLa-H and persistently infected HeLa-H cells (approximately 3 × 10^5^ cells) were subcultured in 2 ml of serum-free Eagle\'s minimum essential medium (EMEM) containing the EAV5′24 PPMO or SCR PPMO at concentrations of 1 μM, 5 μM, or 10 μM in 6-well plates under conditions designed to mirror the antiviral experiments below. After 6 h treatment at 37 °C, 2 ml of EMEM containing 10% bovine calf serum was added. Cell viability was determined by comparing PPMO-treated to mock-treated cells at 24 h and 48 h post-treatment using the Vi-Cell XR (Beckman Coulter, California) which automates cell viability analysis based on the trypan blue vital dye exclusion method. Under these conditions, no cytotoxicity was observed in normal HeLa-H and persistently infected HeLa-H cells following treatment with either of the PPMO at any of the three concentrations tested (data not shown).

Subsequently, the effect of PPMO on HeLa-H cells persistently infected with EAV was investigated. The 83rd serial passage of the EAV-persistently infected HeLa-H cell line was grown in 6-well plates and subcultured (once every 3 days) for 10 passages (through the 92nd passage) in the presence of EAV5′24 PPMO or SCR PPMO at concentrations of 1 μM, 5 μM, or 10 μM. At each passage level, cells were first subcultured for 6 h in 2 ml of serum-free EMEM containing the respective concentration of each PPMO, or no PPMO, followed by addition of 2 ml of EMEM containing 10% bovine calf serum. Tissue culture supernatants at each passage level were harvested and evaluated for infectious virus by plaque assay in rabbit kidney cells (RK-13, ATCC CCL-37) as described previously ([@bib15]). Both standard RT-PCR (sRT-PCR) and real-time RT-PCR (rRT-PCR) analyses of RNA extracted from cell lysates were also carried out at each passage level following previously described procedures ([@bib4], [@bib8], [@bib13]). An indirect immunofluorescence assay (IFA) was performed at selected passage levels of cells using monoclonal antibody (MAb) 12A4 against the EAV nonstructural protein-1 (nsp1; [@bib33]) and MAb 3E2 against the EAV nucleocapsid (N) protein ([@bib14]) followed by fluorescein-conjugated goat anti-mouse immunoglobulin (Pierce), according to previously described procedures ([@bib35]).

As shown in [Fig. 1](#fig1){ref-type="fig"}A, persistently infected HeLa-H cells receiving treatments of 1 μM EAV5′24 PPMO produced infectious virus with titers similar to untreated cells, throughout the observation period (83rd to 92nd passages). In contrast, virus in persistently infected cell cultures receiving treatments of 5 μM or 10 μM EAV5′24 PPMO gradually decreased in titer over the first three passages, after which no infectious virus was detectable, i.e. from the 87th passage onwards. Parallel results were obtained when EAV RNA was measured by sRT-PCR and rRT-PCR. Cell lysates from persistently infected HeLa-H cells either untreated or treated with 1 μM EAV5′24 PPMO were positive for EAV RNA from the 83rd to 92nd passages ([Fig. 1](#fig1){ref-type="fig"}A), whereas cells treated with 5 μM or 10 μM EAV5′24 PPMO were positive for EAV RNA only from the 83rd to 86th passages, with no EAV RNA detectable from the 87th passages onwards ([Fig. 1](#fig1){ref-type="fig"}A). Representative sRT-PCR and rRT-PCR results are shown in [Fig. 1](#fig1){ref-type="fig"}C and D, respectively. Persistently infected HeLa-H cells receiving various concentrations (1 μM, 5 μM, and 10 μM) of SCR PPMO or no PPMO continued to produce EAV RNA and infectious virus throughout the duration of the study, although some fluctuations in viral titers were observed over time ([Fig. 1](#fig1){ref-type="fig"}B). IFA evaluation was carried out on select passage levels of cells receiving EAV5′24 PPMO, SCR PPMO or no PPMO. The IFA results from the 92nd passage are depicted in [Fig. 2](#fig2){ref-type="fig"}A--F. Cells receiving no PPMO or 5 μM SCR PPMO robustly expressed EAV nonstructural ([Fig. 2](#fig2){ref-type="fig"}A and C) and structural ([Fig. 2](#fig2){ref-type="fig"}B and D) proteins, whereas cells receiving 5 μM EAV5′24 PPMO produced no detectable nonstructural ([Fig. 2](#fig2){ref-type="fig"}E) or structural ([Fig. 2](#fig2){ref-type="fig"}F) proteins. To determine if virus production would resume in cultures after discontinuation of the effective PPMO treatment described above, PPMO treatment was stopped after the 90th passage in a set of replicate cultures that had been receiving 5 μM or 10 μM EAV5′24 PPMO. These cultures were passed seven more times without PPMO treatment (through passage 97). Absence of PPMO treatment did not result in the production of renewed viral RNA, viral antigen or infectious virus as measured by sRT-PCR and rRT-PCR, IFA and plaque assay, respectively. Representative RT-PCR and IFA results for the PPMO-cured PI97 cells are shown in [Fig. 1](#fig1){ref-type="fig"}C and D and [Fig. 2](#fig2){ref-type="fig"}G and H. Together, these findings demonstrate that EAV infection was eliminated from persistently infected HeLa-H cells passaged in the presence of 5--10 μM EAV5′24 PPMO. Our results also further confirm the importance of the 5′-terminal region of the genome in the amplification-cycle of EAV ([@bib32]).Fig. 1Effect of PPMO on HeLa-H cells persistently infected with EAV (strain VB). Persistently infected HeLa-H cells (83rd passage, PI83) were subcultured for 10 passages in the presence of 0 μM, 1 μM, 5 μM, or 10 μM of EAV5′24 PPMO or SCR PPMO. Supernatants from each passage were harvested and titrated by plaque assay as described in the text. The average results from two experiments are presented (A, EAV5′24 PPMO; B, SCR PPMO). In parallel, standard RT-PCR (sRT-PCR) and real-time RT-PCR (rRT-PCR) analysis were carried out with RNA extracted from cell lysates at each passage and the results are shown below each graph (+RT-PCR, positive; −RT-PCR, negative). Representative sRT-PCR (expected PCR product size is 185 bp) and rRT-PCR results of persistently infected HeLa-H cells treated with 5 μM EAV5′24 PPMO (PI83 to PI92) are shown in C and D, respectively. Also included is RT-PCR analysis of PPMO-cured PI97 HeLa-H cells in which the 5 μM EAV5′24 PPMO treatment was stopped after passage 90.Fig. 2Representative IFA images. PI92 HeLa cells having received treatments with no PPMO (A and B), 5 μM SCR PPMO (C and D), or 5 μM EAV5′24 PPMO (E and F) between passages 84 and 92 were subject to IFA, respectively using MAb 12A4 against EAV nsp1 protein (αnsp1) and MAb 3E2 against EAV nucleocapsid protein (αN) followed by fluorescein-conjugated goat anti-mouse immunoglobulin. The cell nucleus was stained by Hoechst 33342 (blue color). Also included is the IFA image of PPMO-cured PI97 HeLa-H cells in which 5 μM EAV5′24 PPMO treatment was stopped after passage 90 (G and H). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)

In a previous study we demonstrated that both the virulent Bucyrus (VB) strain of EAV and the EAVP80 virus recovered from the 80th passage of persistently infected HeLa-H cells could readily establish persistent infection in normal HeLa-H cells ([@bib35]). With this in mind, we decided to investigate the growth kinetics of VB and EAVP80 viruses in HeLa-H cells cured of virus persistence by PPMO treatment. In addition, we investigated if persistent infection with either of these two viruses could be re-established in PPMO-cured HeLa-H cells. As shown in [Fig. 3](#fig3){ref-type="fig"}A, a substantial increase in infectious virus titer was observed in both VB- and EAVP80-infected HeLa-H cells (VB: ∼1.6 log increase; EAVP80: ∼2.7 log increase). In contrast, virus titers did not increase substantially in PPMO-cured HeLa-H cells inoculated with either VB or EAVP80 virus. Consistent with our previous findings, persistent infection could be established in normal HeLa-H cells with VB and EAVP80 viruses ([Fig. 3](#fig3){ref-type="fig"}B). In contrast, persistent infection could not be established with either virus strain in PPMO-cured HeLa-H cells, although low titers of virus could be detected for two passages in VB-inoculated and for five passages in EAVP80-inoculated cells ([Fig. 3](#fig3){ref-type="fig"}). These results demonstrate that the PPMO-cured HeLa-H cells were significantly less receptive than normal HeLa-H cells to re-infection with EAV. Factors contributing to the greatly reduced susceptibility of PPMO-cured HeLa-H cells to re-infection with EAV and to the re-establishment of virus persistence remain to be elucidated. The PPMO-cured PI97 HeLa-H cells evaluated in this study were obtained after treatment of persistently infected cells with 5 μM EAV5′24 PPMO for seven passages (84--90th) followed by seven more passages (91st to 97th) without PPMO treatment; it is therefore unlikely that residual PPMO made the cells resistant to re-infection with EAV. It would be of interest to compare expression levels of EAV receptors on PPMO-cured HeLa-H cells to those present on normal HeLa-H cells, but unfortunately, the cellular receptors involved in EAV infection have not as yet been clearly identified.Fig. 3Comparison of the VB and EAVP80 viruses in normal HeLa-H cells and in PPMO-cured HeLa-H cells. (A) Growth characteristics of the VB and EAVP80 viruses in normal HeLa-H cells and in PPMO-cured HeLa-H cells. Subconfluent monolayers of normal HeLa-H and PPMO-cured PI97 HeLa-H cells were grown in 6-well plates and inoculated with each virus (moi of 3) at 37 °C for 1 h. After removal of the inoculum, the cells were rinsed three times with PBS and overlaid with 4 ml of EMEM. At indicated time points, supernatants were harvested and titrated by plaque assay. The average results from four experiments are shown. (B) Attempt to establish persistent infection with the VB and EAVP80 viruses in normal HeLa-H cells and PPMO-cured HeLa-H cells. Subconfluent monolayers of normal HeLa-H and PPMO-cured PI97 HeLa-H cells grown in T-25 flasks were inoculated with each virus at a moi of 3. Following 1 h adsorption at 37 °C, cell monolayers were washed three times with PBS and 10 ml of fresh culture medium was added. Inoculated cultures were incubated at 37 °C and subcultured once every 4 days. Tissue culture supernatants from serial subcultures up to the 10th passage were harvested and titrated for virus by plaque assay. The average results from three experiments are shown.

PPMO targeting viral sequences have been shown to inhibit amplification of a number of RNA viruses *in vitro* and *in vivo* (reviewed by [@bib26]). However, antiviral studies with PPMO reported to date have been limited to acute viral infection models. In this study, we investigated the effects of PPMO on HeLa-H cells persistently infected with EAV. Treatment with an antisense PPMO targeting the EAV 5′-terminus at concentrations of 5--10 μM eliminated the virus from persistently infected HeLa-H cells, and the cells were confirmed free of EAV and EAV nucleic acid on subsequent passages in the absence of PPMO. Although our results indicate that PPMO can eliminate persistent EAV infection in cell culture, the efficacy of PPMO against EAV *in vivo* remains to be evaluated. Unfortunately no satisfactory small animal model for EAV infection exists. To investigate possible elimination of the carrier state in the stallion by PPMO, several complex issues would need to be addressed, including the potential toxicity of therapeutically relevant levels of PPMO in equines and the delivery of effective dosing of PPMO to the equine male reproductive tract. Nevertheless, the results of this *in vitro* study suggest that consideration of such *in vivo* investigation may be warranted.
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